Introduction of a New Recombinant Vaccine Based on Grp78 for Breast Cancer Immunotherapy and Evaluation in a Mouse Model

Introduction of a New Recombinant Vaccine Based on Grp78 for Breast Cancer Immunotherapy and Evaluation in a Mouse Model Publisher

Zare H¹ ; Bakherad H^{2, 3} ; Esfahani AN² ; Norouzi M² ; Aghamollaei H⁴ ; Gargari SLM⁵ ; Mahmoodi F⁶ ; Aliomrani M⁷ ; Ebrahimizadeh W⁸

Show Affiliations

1. Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran
2. Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
3. Pharmaceutical Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
4. Chemical Injuries Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
5. Department of Biology, Faculty of Basic Science, Shahed University, Tehran, Iran
6. Department of Biology, College of Sciences, Shiraz University, Shiraz, Iran
7. Department of Pharmacology and Toxicology, Isfahan Pharmaceutical Science Research Center, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
8. Department of Surgery, Division of Urology, McGill University, the Research Institute of the McGill University Health Centre (RI MUHC), Montreal, QC, Canada

Source: BioImpacts Published:2023

Abstract

Introduction: Breast cancer is one of the most prevalent malignancies in women. Several treatment options are available today, including surgery, chemotherapy, and radiotherapy. Immunotherapy, as a highly specific therapy, involves adaptive immune responses and immunological memory. In our present research, we used the recombinant C-terminal domain of the GRP78 (glucose- regulated protein 78) protein to induce an immune response and investigate its therapeutic impact in the 4T1 breast cancer model. Methods: BALB/c mice were immunized with the cGRP78 protein. The humoral immune response was assessed by ELISA. Then, BALB/c mice were injected subcutaneously with 1×106 4T1 tumor cells. Subsequently, tumor size and survival rate measurements, MTT, and cytokine assays were performed. Results: The animals receiving the cGRP78 vaccine showed significantly more favorable survival and slower tumor growth rates compared with unvaccinated tumor-bearing mice as the negative control mice. Circulating levels of tumoricidal cytokines such as IFNγ were higher, whereas tolerogenic cytokines such as IL-2, 6, and 10 either did not increase or had a decreasing trend in mice receiving cGRP78. Conclusion: cGRP78 vaccines generated potent immunotherapeutic effects in a breast cancer mouse model. This novel strategy of targeting the GRP78 protein can promote the development of cancer vaccines and immunotherapies for breast cancer malignancies. © 2024 The Author(s).

2. Comparison of Mucin-1 in Human Breast Cancer and Canine Mammary Gland Tumor: A Review Study, Cancer Cell International (2022)

3. Association of Grp78, Hif-1Α and Bag3 Expression With the Severity of Chronic Lymphocytic Leukemia, Anti-Cancer Agents in Medicinal Chemistry (2020)

4. The Role of Bip and the Ire1α–Xbp1 Axis in Rhabdomyosarcoma Pathology, Cancers (2021)

Experts (# of related papers)

Reza Afrisham (1)

Style	Citing Format
MLA	Zare H, et al.. "Introduction of a New Recombinant Vaccine Based on Grp78 for Breast Cancer Immunotherapy and Evaluation in a Mouse Model." BioImpacts, vol. 14, no. , 2023, pp. -.
APA	Zare H, Bakherad H, Esfahani AN, Norouzi M, Aghamollaei H, Gargari SLM, Mahmoodi F, Aliomrani M, Ebrahimizadeh W (2023). Introduction of a New Recombinant Vaccine Based on Grp78 for Breast Cancer Immunotherapy and Evaluation in a Mouse Model. BioImpacts, 14(), -.
Chicago	Zare H, Bakherad H, Esfahani AN, Norouzi M, Aghamollaei H, Gargari SLM, Mahmoodi F, Aliomrani M, Ebrahimizadeh W. "Introduction of a New Recombinant Vaccine Based on Grp78 for Breast Cancer Immunotherapy and Evaluation in a Mouse Model." BioImpacts 14, no. (2023): -.
Harvard	Zare H et al. (2023) 'Introduction of a New Recombinant Vaccine Based on Grp78 for Breast Cancer Immunotherapy and Evaluation in a Mouse Model', BioImpacts, 14(), pp. -.
Vancouver	Zare H, Bakherad H, Esfahani AN, Norouzi M, Aghamollaei H, Gargari SLM, et al.. Introduction of a New Recombinant Vaccine Based on Grp78 for Breast Cancer Immunotherapy and Evaluation in a Mouse Model. BioImpacts. 2023;14():-.
BibTex	@article{ author = {Zare H and Bakherad H and Esfahani AN and Norouzi M and Aghamollaei H and Gargari SLM and Mahmoodi F and Aliomrani M and Ebrahimizadeh W}, title = {Introduction of a New Recombinant Vaccine Based on Grp78 for Breast Cancer Immunotherapy and Evaluation in a Mouse Model}, journal = {BioImpacts}, volume = {14}, number = {}, pages = {-}, year = {2023} }
RIS	TY - JOUR AU - Zare H AU - Bakherad H AU - Esfahani AN AU - Norouzi M AU - Aghamollaei H AU - Gargari SLM AU - Mahmoodi F AU - Aliomrani M AU - Ebrahimizadeh W TI - Introduction of a New Recombinant Vaccine Based on Grp78 for Breast Cancer Immunotherapy and Evaluation in a Mouse Model JO - BioImpacts VL - 14 IS - SP - EP - PY - 2023 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract